Hikal Ltd vs Solara Active Pharma Sciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 02, 2026

Key Highlights

The Latest Trading Price of Hikal Ltd is ₹ 189.85 as of 30 Apr 15:30 . The P/E Ratio of Hikal Ltd changed from 13.3 on March 2021 to 54.4 on March 2025 . This represents a CAGR of 32.54% over 5 yearsThe P/E Ratio of Solara Active Pharma Sciences Ltd changed from 22.6 on March 2021 to 3943 on March 2025 . This represents a CAGR of 180.78% over 5 years The Market Cap of Hikal Ltd changed from ₹ 1769 crore on March 2021 to ₹ 4933 crore on March 2025 . This represents a CAGR of 22.76% over 5 yearsThe Market Cap of Solara Active Pharma Sciences Ltd changed from ₹ 5009 crore on March 2021 to ₹ 2005 crore on March 2025 . This represents a CAGR of -16.73% over 5 years The revenue of Hikal Ltd for the Dec '25 is ₹ 497.1 crore as compare to the Sep '25 revenue of ₹ 320.4 crore. This represent the growth of 55.15% The revenue of Solara Active Pharma Sciences Ltd for the Dec '25 is ₹ 349 crore as compare to the Sep '25 revenue of ₹ 314.03 crore. This represent the growth of 11.14% The ebitda of Hikal Ltd for the Dec '25 is ₹ 47.5 crore as compare to the Sep '25 ebitda of ₹ 9.1 crore. This represent the growth of 421.98% The ebitda of Solara Active Pharma Sciences Ltd for the Dec '25 is ₹ 30.59 crore as compare to the Sep '25 ebitda of ₹ 35.22 crore. This represent the decline of -13.15% The net profit of Hikal Ltd changed from ₹ 5.1 crore to ₹ -5.9 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Solara Active Pharma Sciences Ltd changed from ₹ -13.46 crore to ₹ -17.43 crore over 7 quarters. This represents a CAGR of 15.92% The Dividend Payout of Hikal Ltd changed from 18.52 % on March 2021 to 10.87 % on March 2025 . This represents a CAGR of -10.11% over 5 yearsThe Dividend Payout of Solara Active Pharma Sciences Ltd changed from 11.38 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 years .

About Hikal Ltd

Hikal Limited, incorporated on July 8, 1988, has emerged as one of the preferred partners for global companies in segments such as pharmaceuticals, crop protection, animal health, biocides, and specialty chemicals.
The Company is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Company has 5 manufacturing facilities across three states in India.
It supply products to customers across the globe in the US, Japan, Europe, Canada, South East Asia, LATAM, India and RoW. Apart from this, it specialize in manufacturing APIs and intermediates in pharmaceutical division.
Within pharmaceutical division, it offer human health and animal health products. Hikal commenced its first project in 1991 at its first greenfield site at M.

About Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Limited was incorporated on February 23, 2017 to undertake business in manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of and dealing in active pharmaceutical ingredients (APIs).
The Company has 6 APIs manufacturing plants located in Ambernath, Mangalore, Mysuru, Puducherry, Vishakhapatnam, and Cuddalore with a capacity of over 2,580 kilo litres and two R&D Centres in Chennai and Bengaluru. The Company offer rich basket of niche high-value products for global markets.
The Company has developed 80+ commercial APIs predominantly in anthelmintic, anti-malarias, anti-infective, neuromuscular insomnia and anti-psychotic hyperkalemia segments, among others.
These drugs primarily deal with anthelmintic, anti-malarias, beta blockers, muscle relaxants, novel oral anticoagulants, anti-infective and other niche segments.

FAQs for the comparison of Hikal Ltd and Solara Active Pharma Sciences Ltd

Which company has a larger market capitalization, Hikal Ltd or Solara Active Pharma Sciences Ltd?

Market cap of Hikal Ltd is 2,340 Cr while Market cap of Solara Active Pharma Sciences Ltd is 1,803 Cr

What are the key factors driving the stock performance of Hikal Ltd and Solara Active Pharma Sciences Ltd?

The stock performance of Hikal Ltd and Solara Active Pharma Sciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Hikal Ltd and Solara Active Pharma Sciences Ltd?

As of May 2, 2026, the Hikal Ltd stock price is INR ₹189.85. On the other hand, Solara Active Pharma Sciences Ltd stock price is INR ₹498.6.

How do dividend payouts of Hikal Ltd and Solara Active Pharma Sciences Ltd compare?

To compare the dividend payouts of Hikal Ltd and Solara Active Pharma Sciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.